Tradestie Institutional Equity Comparison Engine

BGMSP vs CRIS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRIS Overall Edge

CRIS Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Curis Inc (CRIS) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, BGMSP trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CRIS at N/M Forward P/E and -833.4% operating margin (-66.0% YoY). In options structure, BGMSP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CRIS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CRIS
BGMSP N/M vs CRIS N/M Fwd P/E
Growth & Margin Winner CRIS
Op Margin N/A vs -833.4% ยท YoY N/A vs -66.0%
Momentum & Technical Winner CRIS
1Y -72.6% vs -61.0% ยท 52W Pos 0% vs 4%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
1M Return -60.98%
1Y Return -72.57%
Forward P/E N/M
Unified AI Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
CRIS NASDAQ
Curis Inc
Biological Products, (No Disgnostic Substances)
$0.44
-1.07% 1D
Market Cap $3.8M
1M Return +8.14%
1Y Return -61.04%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 15.0 Fund 41.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGMSP -72.57% CRIS -61.04% Spread: +30.39 pp (CRIS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGMSP TTM Op. Margin: N/A CRIS TTM Op. Margin: -833.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGMSP vs CRIS. Trailing 12-month operating profitability (BGMSP N/A vs CRIS -833.4%) and valuation multiples (BGMSP N/M vs CRIS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGMSP (2) vs CRIS (7)
Institutional Metric BGMSP CRIS Criterion Row Winner
Market Capitalization Scale N/A $3.8M Larger Scale CRIS
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple CRIS
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -66.0% Higher Growth CRIS
Operating Margin (TTM) Profitability N/A -833.4% Higher Margin CRIS
Net Profit Margin Profitability N/A 0.0% Higher Margin CRIS
Return on Equity (ROE) Capital Efficiency N/A -693.9% Higher ROE CRIS
52-Week Range Position Momentum 0% ($1โ€“$14) 4% ($0โ€“$7) Stronger Trend CRIS
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 201% Vol 11.40ฮฒ ยท 269% Vol Lower Realized Risk BGMSP
Unified Institutional Score Composite Signal 42.7 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite BGMSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGMSP vs CRIS Buy Guide
BGMSP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGMSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRIS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CRIS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGMSP nor CRIS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.